11. April 2019

Transglutaminase 6 at SRCA International Meeting!



Zedira kits


Zedira Logo                                                                                                                                                                     Transglutaminase-Newsletter | April 2019




Be aware of TG6!

Gluten-sensitive neurological disorders like Gluten ataxia may be accompanied by auto- antibodies to neuronal transglutaminase (TG6).

Detection of TG6-autoantibodies in human sera is possible using our ELISA-Kits E103 (anti-TG6-IgA) and E104 (anti-TG6-IgG).

Further, in co-operation with the medical laboratory of Prof. Dr. med. M. Kramer (board-certified clinical pathologist) in Heidelberg, Germany we provide testing services for the determination of Transglutaminase auto-antibodies in patient serum samples.

Please refer to our website: zedira.com/Celiac-disease-products

Gain more insights!

Learn more about TG6-autoantibodies in neurology at the 10th International Meeting of the Society for Research on the Cerebellum and Ataxias (SRCA), taking place in Sheffield, Great Britain, form 16 to 17 May 2019.

In the day 2 session "Pathophysiology of autoimmune ataxias" talks by Marios Hadjivassiliou and Daniel Aeschlimann will point out the role of transglutaminase 6 in gluten ataxia.


Neuronal Transglutaminase, TG6

Art. No. Name Unit Price

T021 Human neuronal transglutaminase

250 µg 475 €
E103

ZediXclusive TG6-ab ELISA (IgA) 1 kit/
96 wells

520 €
E104 ZediXclusive TG6-ab ELISA (IgG)

1 kit/
96 wells
 
520 €
A139 Monoclonal antibody to transglutaminase 6 (Catalytic Domain)

200 µg 365 €

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • CELIACHIA 2020

    07.02.2020 - 08.02.2020
    Milan, Italy

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA

  • Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland